Peripheral artery disease (PAD) is associated with exercise impairment and greater thrombotic risk. We investigated whether clot formation and platelet aggregation assessed by thromboelastography and light-transmission aggregometry correlate with the severity of symptomatic PAD assessed by ambulatory function measures. We studied 40 symptomatic patients with PAD in whom severity of disease was assessed using ankle-brachial index, peak walking time (PWT), claudication onset time, peak oxygen uptake, daily ambulatory activity, and walking impairment questionnaire (WIQ) scores. Clot strength correlated negatively with peak oxygen uptake, PWT, WIQ distance, and stair-climbing scores. Time to clot formation did not correlate with exercise parameters. Platelet aggregation was negatively correlated with WIQ distance score and was positively correlated with PWT and peak oxygen uptake. In conclusion, clot strength and platelet aggregation correlated with objective and self-perceived ambulatory measures. Patients with PAD having more severe walking impairment may be likely to form stronger clots.
Introduction
Peripheral artery disease (PAD) affects approximately 8 million Americans. 1 Patients with PAD have significant ambulatory limitations associated with intermittent claudication and higher cardiovascular morbidity and mortality. [1] [2] [3] Platelet reactivity and clotting play a pivotal role in the genesis of arterial thrombotic events. Hence antiplatelet agents are considered an important therapeutic option in reducing adverse vascular outcomes in high-risk patients. [4] [5] [6] [7] Several studies have reported increased platelet reactivity in patients with moderate to severe symptomatic PAD compared with healthy controls, and platelet function appears to correlate with disease severity indicated by lower ankle-brachial index (ABI) and worse symptoms. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] None of these studies correlated platelet aggregation with actual quantified measures of exercise performance and walking impairment. Although it has been shown that elderly patients with PAD form denser and poorly lysable fibrin clots when compared to healthy controls, 19 it is unknown whether clot formation parameters correlate with the degree of exercise performance capacity in symptomatic patients with PAD. We therefore sought to study this association in patients with PAD having intermittent claudication.
Methods Patients
This analysis included 40 symptomatic patients with lower extremity PAD from a cohort of patients enrolled in a prospective, randomized controlled clinical trial that compared a home-based exercise program with a supervised exercise program and its impact on exercise performance at the General Clinical Research Center at the University of Oklahoma Health Sciences Center from September 2004 to April 2007. 20 Patients who had intermittent claudication secondary to vascular insufficiency were included if they had a history of any type of exertional leg pain, ambulation during a graded treadmill test was limited by leg pain consistent with intermittent claudication, and an ABI 0.90 at rest or an ABI 0.73 after exercise. Patients were excluded for the following conditions: (1) absence of PAD (ABI > 0.90 at rest and ABI > 0.73 after exercise), (2) inability to obtain an ABI measure because of noncompressible vessels, (3) asymptomatic PAD determined from the medical history and verified during the graded treadmill test, (4) use of cilostazol and pentoxifylline initiated within 3 months before investigation because these drugs may improve the patient's ambulatory function, 21 (5) exercise tolerance limited by factors other than leg pain, and (6) active cancer, renal disease, or liver disease.
The local institutional review board approved the study and only those that signed a written informed consent were included. Baseline demographic and clinical characteristics were collected on each patient in addition to a detailed physical examination.
Ambulatory and Exercise Performance Assessment
Objective and self-reported measures of ambulatory and exercise performance were obtained at baseline before beginning an exercise program.
Self-reported physical activity level was assessed with the Baltimore Activity Scale for Intermittent Claudication (BASIC) questionnaire. 22 Self-reported ambulatory ability was assessed using the walking impairment questionnaire (WIQ) that evaluates the ability to walk at various speeds and distances and to climb stairs. 23 Ankle-brachial index was determined by obtaining the ankle and brachial systolic blood pressures. 20 Patients with intermittent claudication performed a progressive, graded treadmill protocol (2 mph, 0% grade with 2% increase every 2 minutes) until maximal claudication pain occurred. The claudication onset time (COT), the peak walking time (PWT), and peak oxygen uptake were obtained. Claudication onset time was defined as the walking time at which the patient first experienced pain, and PWT was defined as the time at which ambulation could not continue because of maximal pain. 20 Peak oxygen uptake was measured as described previously 24 ; the ischemic window was expressed as an area under the curve of the resting ankle systolic BP and its recovery from a maximal graded treadmill test. Daily Ambulatory Activity (steps/d) was measured with a step activity monitor (StepWatch3, Orthoinnovations, Inc, Oklahoma City, Oklahoma) during 7 consecutive days at baseline. None of the exercise interventions were included in the monitoring period. The monitor, attached to the right ankle above the lateral malleolus with elastic Velcro straps, continuously recorded the number of strides taken on a minute-to-minute basis. 20 
Measures of Clot Formation and Platelet Aggregation
Whole blood samples were obtained at baseline. Clot formation parameters were measured by thrombelastography (TEG). Within 2 hours of drawing, citrated whole blood was activated with kaolin; calcium citrate was added to obtain the thrombininduced clot. The TEG Hemostasis System (Haemonetics Corporation, Braintree, Massachusetts) provided quantitative measurements of the physical properties of the clot, such as the clot strength (MA) and the time to clot formation (R). Both parameters were compared with a normal range of values provided by the test manufacturer, which is based on the lot of kaolin used to initiate the reaction (upper limit for MA is 69 or 71 mm and lower limit for R is 2 or 5 minutes, based on the batch of kaolin reagent used for each patient).
Platelet aggregation was measured by light transmission aggregometry. Within 3 hours of drawing, the sample was centrifuged at 208g for 10 minutes to obtain platelet-rich plasma and at 1302g for 15 minutes to obtain platelet-poor plasma. Platelet aggregation was measured using a Chrono-log 490-4D Aggregometer (Chrono-log Corporation, Havertown, Pennsylvania). Platelet-rich plasma was stimulated with agonists that stimulate different pathways involved in platelet activation to distinguish a drug-related effect: thrombin receptor-activated peptide (TRAP) 2 and 20 mmol/L, arachidonic acid (AA) 0.5 mg/mL (1.5 mmol/L), and adenosine diphosphate (ADP) 5 and 20 mmol/L. Aggregation was expressed as the maximal percentage change in light transmittance from baseline.
Statistical Analyses
A Spearman rank correlation coefficient was used to quantify the association between measures of clot formation and platelet aggregation and PAD severity. Partial correlation coefficients were estimated after adjustment for potential confounding factors including smoking status, diabetes status, dyslipidemia, and hypertension. A Wilcoxon rank-sum test was used to compare the median clot formation measures between subgroups of patients defined by medication use. A 2-sided .05 a level was used and a P value .05 was considered significant. Given the exploratory nature of this project, no formal adjustment was made for multiple hypothesis testing among the exercise performance measures, clot formation, or platelet aggregation measures. Data were analyzed using SAS (SAS System for Windows, ver. 9.2, SAS Institute Inc., Cary, North Carolina).
Results
Forty symptomatic patients with PAD were included in this cross-sectional study. Baseline demographic and clinical characteristics are summarized in Table 1 .
The exercise performance characteristics are summarized in Table 2 . Patients in this study had considerable walking impairment typically seen in patients with claudication as reflected by their BASIC total score, COT, PWT, peak oxygen uptake, ischemic window, WIQ scores, and daily ambulatory activity.
Clot formation parameters and platelet aggregation measures are summarized in Table 3 . No significant differences were found in clot formation parameters, when comparing patients who were (n ¼ 5) and were not (n ¼ 32) taking warfarin for various medical conditions other than PAD, such as atrial fibrillation and valvular heart disease (data not shown). Twelve patients presented either increased clot strength or shorter time to clot formation when compared with the normal range provided by the manufacturer's controls. Ten (27%) patients had MA greater than the upper limit of normal and 2 (5%) patients had R of less than the lower limit of normal, while none of the patients had both parameters outside the established range.
The associations between measures of ambulatory function and clot formation and platelet aggregation, after adjustment for clinically significant risk factors (smoking, diabetes, dyslipidemia, and hypertension), are shown in Table 4 . Clot strength (MA) was negatively correlated with peak oxygen uptake (P ¼ .001) and WIQ distance score (P ¼ .050) as well as WIQ stair-climbing score (P ¼ .002). Table 5 shows that these associations remained largely unchanged when only those patients who were not using warfarin and had available exercise parameter measures (n ¼ 29) were considered (peak oxygen uptake, P ¼ .0002, and WIQ stair climbing score, P ¼ .0069). In addition, a negative association between MA and PWT was also found (P ¼ .017). Time to clot formation (R) was not significantly correlated with any of the ambulatory function measures even after excluding patients who were using warfarin as shown in Tables 4 and 5 .
In addition, several associations between measures of ambulatory function and platelet aggregation were found as shown in Table 4 . Platelet aggregation induced by AA was negatively correlated with WIQ distance score (P ¼ .050). This negative correlation remained among patients who were not using aspirin (n ¼ 10), although it was not statistically significant (r ¼ À.80, P ¼ .054). On the other hand, platelet response to low-and high-dose TRAP was positively correlated with PWT (P ¼ .003 and P ¼ .018, respectively) and peak oxygen uptake (P ¼ .025 and P ¼ .042, respectively). Platelet aggregation induced by ADP did not correlate with any of the ambulatory function measures. Since P2Y12 inhibition by clopidogrel can affect ADPinduced platelet aggregation, 21, 25 when only patients not using clopidogrel (n ¼ 22) were analyzed, platelet aggregation was not associated with any of the ambulatory function measures.
Discussion
Our primary finding was a negative correlation between clot strength and both objectively measured exercise parameters (peak oxygen uptake and PWT) and self-perceived ambulatory function (WIQ distance and stair-climbing scores) in patients with PAD having intermittent claudication. This suggests that clot strength may be lower in patients with better ambulatory function. Further analysis of only patients who were not using warfarin confirmed our initial results, and the established associations between clot strength and specific exercise parameters appeared to be stronger. On the other hand, time to clot formation was not significantly related to any exercise parameters, suggesting that the period of latency until the initial fibrin formation is not related to the patient's walking impairment. This is the first study to compare quantitative clot formation parameters with validated measures of ambulatory function, as opposed to ABI alone, to assess both functional limitations and disease severity in patients with PAD having claudication. Of particular importance, clot strength was correlated with exercise parameters but not with ABI in patients with intermittent claudication, suggesting that clot strength is more strongly related to the functional impairment of PAD than to the vascular severity of disease.
The negative correlations between clot strength and peak oxygen uptake (a measure of whole body oxygen uptake and aerobic fitness) and PWT imply that the clot is stronger in patients with PAD who are less fit and walk less. In addition, the negative association between the clot strength and the WIQ distance and stair-climbing scores suggests that the clot is stronger among those who have severe self-perceived ambulatory impairment. Formation of a stronger clot in patients with worse walking impairment may contribute to the greater thrombotic risk seen in those with more severe disease. However, our study did not assess adverse vascular outcomes and this remains to be investigated in larger studies.
Clot strength is a measure of platelet contribution to clot formation through platelet-fibrin bonding. Since it is well established that patients with PAD have increased platelet reactivity when compared with healthy controls, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] our secondary objective was to evaluate any associations between platelet aggregation and validated measures of walking performance in patients with PAD having claudication.
We found a negative correlation between platelet aggregation induced by AA and self-perceived ambulatory function reflected by the WIQ distance score. This indicates that patients who poorly perceived their ambulatory ability to walk at various distances at a constant speed had higher platelet aggregation triggered by this agonist. Although this relationship was not seen with COT and PWT, these measures are obtained during a standardized treadmill test and may not reflect perceived ambulatory tasks that are performed throughout the course of an entire day. Aspirin can block platelet aggregation triggered by AA, 21, 25, 26 but this association remained among those patients who did not use this drug, although the P value was not statistically significant probably due to the small sample size.
The finding that symptomatic patients with PAD with better exercise performance and aerobic fitness (measured by PWT and peak oxygen uptake) have greater TRAP-induced platelet aggregation is contrary to what we expected. Plausible causes for such discrepancy include but are not limited to: (1) concomitant use of antiplatelet agents in some but not all patients, (2) noninclusion of patients with critical limb ischemia who are more likely to have increased platelet aggregation, and (3) in vitro testing that may not be reflective of in vivo mechanisms.
Opposing results in the association between platelet aggregation induced by different agonists and walking impairment in these patients may suggest that platelet aggregation is not the sole factor associated with morbidity and poor performance in patients with PAD. Other clot forming parameters may also be relevant to disease progression and there may be other pathways through which platelets contribute to clot strength that were not measured in this study and deserve further investigation.
This study has inherent limitations. The associations between walking performance measures and platelet function tests from this cross-sectional design do not allow causality to be established. The present findings are also limited by the relatively small sample size, which may explain why some of the associations found are not very strong and some comparisons were not statistically significant. Results were not compared with agematched controls, but the clot strength and time to clot formation were compared with a normal range of values provided by the test manufacturer. Correlation of walking performance measures with other tests that evaluate the coagulation cascade, such as bleeding time, may be needed to validate our findings. We recognize that many correlation coefficients were calculated, given the exploratory nature of this study, without adjustment for the inflated false-positive error rate. Also, given the small sample size, no formal regression model building was performed to identify exercise performance characteristics independently associated with clot formation parameters or platelet aggregation. Therefore, our results are preliminary and further studies are needed to confirm our observations. Additionally, this study is limited to patients with PAD who have intermittent claudication and may not be generalized to patients with less or more severe disease. The effect of exercise training on clot formation is currently being evaluated as a second phase of this study.
Conclusions
In patients with PAD having intermittent claudication, clot strength and platelet aggregation correlated with objective and self-perceived ambulatory measures. Patients with PAD having more severe walking impairment may be likely to form stronger clots.
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